---
figid: PMC6293987__nihms-995765-f0001
figtitle: Components of the phosphoinositide 3-kinase (PI3K) signaling pathway and
  its associated therapeutic targets
organisms:
- Homo sapiens
- Mus musculus
- Nicotiana tabacum
- Human papillomavirus
organisms_ner:
- Homo sapiens
- Mus musculus
- Drosophila melanogaster
pmcid: PMC6293987
filename: nihms-995765-f0001.jpg
figlink: /pmc/articles/PMC6293987/figure/F1/
number: F1
caption: 'Binding of growth factors and cytokines to a receptor tyrosine kinase (RTK)
  located on the cell membrane activates class I PI3K, which is a heterodimer of p85
  and a p110 isoform (p110α is illustrated here). The catalytic subunit of PI3K (p110α)
  phosphorylates phosphatidylinositol 4,5-biphosphate (PIP2), generating phosphatidylinositol
  (3,4,5)-triphosphate (PIP3). PIP3 activates protein kinase B (Akt), which subsequently
  triggers mTOR (mechanistic target of rapamycin) activity. Therapeutic targets that
  inhibit various components of this signaling pathway include the following: p110α
  inhibitor (alpelisib/BYL719), pan PI3K inhibitors (buparlisib/BKM120, copanlisib/BAY-80–6946,
  PX-866, and SF1126), dual PI3K/mTOR inhibitor (BEZ-253), Akt inhibitor (MK-2206),
  and mTOR inhibitors (sirolimus/rapamycin, everolimus, and temsirolimus).'
papertitle: Therapeutic Implications of the Genetic Landscape of Head and Neck Cancer.
reftext: Janice Cho, et al. Semin Radiat Oncol. 2018 Jan;28(1):2-11.
year: '2018'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.962768
figid_alias: PMC6293987__F1
figtype: Figure
redirect_from: /figures/PMC6293987__F1
ndex: ff0998ef-de8f-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6293987__nihms-995765-f0001.html
  '@type': Dataset
  description: 'Binding of growth factors and cytokines to a receptor tyrosine kinase
    (RTK) located on the cell membrane activates class I PI3K, which is a heterodimer
    of p85 and a p110 isoform (p110α is illustrated here). The catalytic subunit of
    PI3K (p110α) phosphorylates phosphatidylinositol 4,5-biphosphate (PIP2), generating
    phosphatidylinositol (3,4,5)-triphosphate (PIP3). PIP3 activates protein kinase
    B (Akt), which subsequently triggers mTOR (mechanistic target of rapamycin) activity.
    Therapeutic targets that inhibit various components of this signaling pathway
    include the following: p110α inhibitor (alpelisib/BYL719), pan PI3K inhibitors
    (buparlisib/BKM120, copanlisib/BAY-80–6946, PX-866, and SF1126), dual PI3K/mTOR
    inhibitor (BEZ-253), Akt inhibitor (MK-2206), and mTOR inhibitors (sirolimus/rapamycin,
    everolimus, and temsirolimus).'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - EGFR
  - PIK3CA
  - AKT1
  - AKT2
  - AKT3
  - ADA2
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - MTOR
  - ARHGEF7
  - CBFA2T2
  - PPP1R13B
  - PPP1R12C
  - Egfr
  - Pik3ca
  - Akt1
  - Pik3r1
  - Mtor
  - Ecm1
  - Ppp1r13b
  - Tie
  - Ras85D
  - InR
  - Akt
  - pan
  - Panx
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Tor
  - Myb
  - Taf5
  - MK-2206
  - BYL719
  - Sirolimus
  - rapamycin
  - Everolimus
  - Temsirolimus
  - BEZ-235
  - SF1126
---
